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Abstract
Background: Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The
unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE).
As the number of cases under treatment with ICIs increases, new types of characteristics of irAE have emerged. This
case report suggests that IgG4-related pleural disease could occur as an irAE.
Case presentation: A 64-year-old man was diagnosed with pulmonary adenocarcinoma stage IIIB. Following
concurrent chemoradiotherapy, durvalumab was administered every two weeks. The patient complained of
dyspnea on effort 4 months after the initiation of durvalumab therapy. Chest CT scans showed mild bilateral pleural
effusion 4 months after the initiation of durvalumab therapy, and the amount of pleural effusion increased further
at 7 months. Durvalumab was thought to be a potential cause of pleural effusion and was withdrawn after 13
courses of administration over 7 months. The level of serum IgG4 was 2750 mg/dL. The levels of IgG4 of the pleural
fluids were 2790 mg/dL on the right side and 2890 mg/dL on the left side at 7 months. Microscopic examination of
the pleural biopsy revealed lymphoplasmacytic infiltration with storiform fibrosis. Immunohistochemical
examinations showed that the number of IgG4-positive cells was > 20/high power field and the percentage of
IgG4-positive to IgG-positive plasma cells was > 50%. Oral prednisolone at a dose of 30 mg/day was initiated, and
remarkable clinical improvements were achieved. After 4 months of prednisolone therapy, the level of serum IgG4
decreased to 370 mg/dL and chest CT revealed the disappearance of bilateral pleural effusion.
Conclusion: This was a case of IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under
durvalumab treatment. To our knowledge, this is the first case report of IgG4-related pleural disease as an irAE. It is
important to consider the possibility of IgG4-related pleural disease in cases of pleural effusion during the
treatment with ICIs.
Keywords: Durvalumab, IgG4-related pleural disease, Immune checkpoint inhibitors, Immune-related adverse
events, Lung cancer
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Background
Immune checkpoint inhibitors (ICIs) are currently the
standard treatment for non-small cell lung cancer
(NSCLC). Recently, the administration of a programmed
death-ligand 1 (PD-L1) inhibitor following concurrent
chemoradiotherapy (CRT) for stage III NSCLC has dem-
onstrated a longer 24-month overall survival of 66.3% than
that of 55.6% for controls [1]. The unique adverse events
that can arise after treatment with ICIs, including pneu-
monitis, colitis, and thyroiditis, are known as immune-
related adverse events (irAE) [2]. As the number of cases
under treatment with ICIs increases, new characteristics
of irAE have been emerged. However, IgG4-related pleural
disease has never been reported as irAE.
Herein, we report a case of IgG4-related pleural dis-
ease in a patient with pulmonary adenocarcinoma under
durvalumab treatment. To our knowledge, this is the
first case report of IgG4-related pleural disease as irAE.
Case presentation
A 64-year-old man was diagnosed with pulmonary
adenocarcinoma stage IIIB. The patient had a smoking
history of 50 packs a year. Immunohistochemical
analysis revealed a PD-L1 tumor proportion score of >
50%. Concurrent CRT using weekly courses of carbopla-
tin plus paclitaxel and 60.0 Gy irradiation over 6 weeks
was performed and partial response was achieved. Con-
solidation immunotherapy was initiated 4 weeks after
the CRT treatment concluded. Durvalumab (10 mg/kg),
an ICI, was administered every 2 weeks. The patient
complained of dyspnea on effort 4 months after the initi-
ation of durvalumab therapy.
Chest X-ray and computed tomography (CT) scans
showed radiation pneumonitis in the irradiated area ac-
companied with mild bilateral pleural effusion (Fig. 1b).
There were no signs of the progression of lung cancer or
thromboembolism. Because pleural effusion was rela-
tively small, the performance of pleurocentesis proved
technically difficult. Spirometry revealed a volume cap-
acity of 1.77 L, a forced expiratory volume in 1 s (FEV1)
of 1.01 L, %FEV1 of 39.2%, and FEV1/forced volume
capacity of 61.0%, suggesting severe obstructive disease
by chronic obstructive pulmonary disease (COPD) com-
bined with constrictive disease by radiation pneumonitis.
Laboratory examination revealed eosinophilia (1165 /μL)
and serum IgE level of 2000 IU/mL, suggesting an
Fig. 1 Clinical course. Chest computed tomography showed the appearance of mild bilateral pleural effusion 4 months after the initiation of
durvalumab (b). Durvalumab was withdrawn after 13 courses of administration over 7 months. There were increases in the amount of bilateral
pleural effusion (c), serum levels of globulin, IgG, and IgG4 8months after the initiation of durvalumab. PSL, at a dose of 30 mg per day, was
started and gradually decreased. PSL therapy for 4 months decreased the level of IgG4 from 2750mg/dL to 370mg/dL and induced complete
disappearance of bilateral pleural effusion (d). LAMA: long-acting muscarinic antagonist; LABA: long-acting beta-agonist; ICS: inhaled corticosteroid;
LTRA; leukotriene receptor antagonist; PSL: prednisolone
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asthma and COPD overlap. The echocardiogram showed
normal cardiac function and pulmonary artery pressure.
The cause of the dyspnea was assumed to be exacerba-
tion of asthma and COPD overlap.
The patient was treated with a long-acting muscarinic
antagonist, a long-acting beta-agonist, a moderate dose
of inhaled corticosteroid, a leukotriene receptor antag-
onist, and a diuretic. The patient was also administered
systemic oral corticosteroid (prednisolone 20mg/day)
for five days and antibiotics (levofloxacin) for seven days
4 months after the initiation of durvalumab therapy.
Despite these treatments, the dyspnea was progressive.
The chest X-ray and CT scans showed increases in the
amounts of bilateral pleural effusion (Fig. 1c). No pro-
gression of radiation pneumonitis or lung cancer was
observed in either lung field. Durvalumab was with-
drawn after 13 courses of administration over 7 months
because there was a possibility that the pleural effusion
was induced by durvalumab. The patient was admitted
for the treatment of pleural effusion.
Physical examination did not show any findings sug-
gesting the presence of collagen vascular diseases. The
levels of C-reactive protein and angiotensin-converting
enzyme were 0.13 mg/dL (normal range < 0.15 mg/dL)
and 8.6 IU/mL (normal range 7.7–29.4 IU/mL), respect-
ively. The T-SPOT test for TB, which measures the
number of interferon-gamma-secreting spot-forming T
cells obtained from a patient stimulated by
Mycobacterium tuberculosis-specific antigens, was nega-
tive. There was an increase in the level of serum im-
munoglobulin of 6.4 g/dL. The level of serum IgG was
4.329 g/dL (normal range 0.87–1.7 g/dL), and among the
IgG subclass, IgG4 was 2.750 g/dL (normal range
0.0045–0.117 g/dL). Serologic studies indicated that an
anti-nuclear antibody was positive. Serum myeloperoxi-
dase- anti-neutrophil cytoplasmic antigen was negative
(< 1.0 U/mL). The levels of thyroid stimulating hormone,
free triiodothyronine, and free thyroxine were 2.92 μIU/
mL (normal range 0.54–4.26 μIU/mL), 2.12 pg/mL (nor-
mal range 2.39–4.06 pg/mL), 0.87 ng/dL (normal range
0.71–1.52 ng/dL), respectively.
Pleurocentesis was performed on each side separately
and revealed unilateral exudative pleural effusion with a
predominance of mononuclear cells with no malignant
cells. Bacterial culture and polymerase chain reaction ana-
lysis of the pleural fluids for Mycobacterium tuberculosis,
avium, or intacellulare DNA were all negative. Adenosine
deaminase concentrations were 47.2 U/L and 49.3 U/L in
the right- and left-sided pleural fluids, respectively. The
levels of IgG and IgG4 of the pleural fluids were 4183mg/
dL and 2790mg/dL on the right side, and 4366mg/dl and
2890mg/dL on the left side.
On the 12th day of hospitalization, a pleural biopsy was
performed using video-associated thoracoscopy and the
specimen was collected from the pleura on the right side.
Microscopic examination revealed lymphoplasmacytic
Fig. 2 (a) Microscopic examination revealed lymphoplasmacytic infiltration with storiform fibrosis. (b) Immunochemical staining showed the
presence of numerous IgG4-positive plasma cells. The number of IgG4-positive cells was > 20/high power field (× 400). (c) Immunochemical
staining showed the presence of IgG-positive plasma cells (× 400)
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infiltration with storiform fibrosis (Fig. 2a). There was no
evidence of granulomas, necrosis, or malignancy. Immu-
nohistochemical examinations showed the presence of nu-
merous IgG4-positive plasma cells. The number of IgG4-
positive cells was > 20/high power field (× 400) (Fig. 2b)
and the percentage of IgG4-positive to IgG-positive
plasma cells (Fig. 2c) was > 50%. These findings indicated
that IgG4-related disease contributed to the pathogenesis
of pleural effusion.
Oral prednisolone at a dose of 30 mg/day was initiated
and remarkable clinical improvements were achieved.
After 4 months of prednisolone therapy, chest CT scans
revealed the complete disappearance of bilateral pleural
effusion (Fig. 1d), the level of serum IgG4 was decreased
to 0.37 g/dL (Fig. 1), and the dyspnea was resolved. Pres-
ently, the patient is under treatment with an oral
corticosteroid and under careful observation for the re-
currence of adenocarcinoma.
Discussion and conclusions
This is a rare case of IgG4-related respiratory and
pleural diseases in a patient with pulmonary adenocar-
cinoma under treatment with an ICI, durvalumab.
Known irAEs that can arise after treatment with ICI in-
clude: pneumonitis, colitis, and thyroiditis [2]. However,
there have been no reports describing IgG4-related
pleural disease as irAE [2, 3].
The criteria of IgG4-related respiratory disease include
an abnormal shadow on chest CT, serum level of IgG4
higher than 135 mg/dL and characteristic findings in tis-
sue specimens [4–6]. In the present case, two pieces of
evidence suggested the contribution of IgG4-related re-
spiratory disease to the pleural effusion: 1. extremely
high concentration of IgG4 in the serum and 2. the con-
centrations of IgG4 in the bilateral pleural effusion that
were higher than that of the serum. This assumption
was further confirmed by the marked IgG4-positive
plasma cell infiltration with characteristic pattern of fi-
brosis in the pleural biopsy specimen. Differential diag-
noses of IgG4-related respiratory diseases in the present
case included malignant lymphoma, multicentric Castle-
man’s disease, collagen vascular diseases, and sarcoidosis
[5, 6]. The finding that there were no increases in the
levels of C-reactive protein, angiotensin-converting en-
zyme, and anti-neutrophil cytoplasmic antigen suggests
that it is unlikely that these diseases were the cause of
pleural effusion in the present case.
Among the eight extant cases describing IgG4-related
pleural disease, three cases reported the levels of IgG4 in
the pleural effusion to be 124 to 653 mg/dL, and in all
eight cases, the levels of serum IgG4 were 136 to 740
mg/dL. Clinical responses to corticosteroid therapy were
observed in these cases [7]. According to another report
describing the clinicopathological features of five cases
of IgG4-related pleural disease, the average age was 62
years, and two patients had no organ involvement other
than pleural involvement [8].
IgG4 itself is considered a non-inflammatory immuno-
globulin and the actual role of IgG4 itself in the process
of IgG4-related disease remains unclear. T helper 2 cells,
CD4+ cytotoxic T cells, and T follicular helper cells are
among the T helper subsets that are thought to be the
drivers of the pathogenesis of IgG4-related diseases. In-
flammatory cytokines produced by activation of these T
helper cells contribute to the expansion of IgG4-
producing plasma cells and activation of fibroblasts.
CD4+ cytotoxic T cells and T follicular helper cells play
key roles in the production of IgG4 by plasmablasts and
plasma cells [9]. Durvalumab, which is a PD-L1 inhibi-
tor, upregulates functions of T cells by inhibiting the
programmed cell death protein 1 (PD-1)/PD-L1 pathway
[10]. T cells, antibodies, and cytokine responses may be
involved in the pathogenesis of irAE [2]. The PD-1/PD-
L1 pathway also contributes to the interaction between
T follicular helper cells and plasmablasts [9]. One pos-
sible mechanism is that the inhibition of PD-1/PD-L1
pathway enhances T follicular helper cells to promote
the growth, differentiation, and class switching of B cells
to IgG4 [11, 12]. Another possibility is that there is an
association between pulmonary adenocarcinoma and
IgG4-related disease. IgG4-related diseases have been
known to have a high incidence of malignancies [13].
However, the latter theory is unlikely because pulmonary
adenocarcinoma was followed by IgG4-related pleural
disease in the present case.
When our patient who had a history of heavy smoking
complained of dyspnea during ICI treatment after CRT
for lung cancer, the differential diagnoses were exacerba-
tion of COPD, cardiac failure, pulmonary thrombo-
embolism, progression of the lung cancer, and radiation
pneumonitis. ICI-related adverse events, such as intersti-
tial pneumonitis were also excluded. Differential diagno-
ses for pleural effusion included pleuritis carcinomatosa,
radiation-induced pleuritis, tuberculosis, cardiac failure,
renal failure, and hypothyroidism [14]. This case report
is novel and relevant because it demonstrates that IgG4-
related respiratory and pleural diseases should be con-
sidered as a differential diagnosis in patients undergoing
ICI with complicating pleural effusion. In the present
case, the increase in the level of serum immunoglobulin
was positively associated with the increase in the amount
of pleural effusion. In such a case, measurement of the
levels of IgG4 in the serum and pleural effusion is
recommended.
IgG4-related disease is frequently accompanied by
bronchial asthma [9, 15]. In the present case, the pres-
ence of COPD was previously known based on the heavy
smoking history and the findings of pulmonary function
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test and chest CT. The level of serum IgE had not mea-
sured prior to durvalumab treatment. The eosinophilia
and the high level of serum IgE emerged following ther-
apy with durvalumab. Eosinophilia and increased levels
of serum IgE, both reported in 40% of patients with
IgG4-related disease, are mediated by inflammatory cy-
tokines released from T helper cells [9, 15]. It is possible
that eosinophilia and the increase in the level of serum
IgE were also induced by ICI as well as IgG-related
pleural disease.
To the best of our knowledge, this is the first report of
IgG4-related respiratory and pleural disease in a patient
with adenocarcinoma during treatment of ICI. It is im-
portant to take into consideration the IgG4-related
pleural disease in a case of pleural effusion during the
treatment with ICIs.
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